Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline Review, H1 2018’, provides an overview of the Lassa Fever (Lassa Hemorrhagic Fever) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Lassa Fever (Lassa Hemorrhagic Fever)

– The report reviews pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Lassa Fever (Lassa Hemorrhagic Fever) therapeutics and enlists all their major and minor projects

– The report assesses Lassa Fever (Lassa Hemorrhagic Fever) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Lassa Fever (Lassa Hemorrhagic Fever) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Celgene Corp

Etubics Corp

GeoVax Labs Inc

Inovio Pharmaceuticals Inc

Kineta Inc

Profectus BioSciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Lassa Fever (Lassa Hemorrhagic Fever) Overview

Lassa Fever (Lassa Hemorrhagic Fever) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Lassa Fever (Lassa Hemorrhagic Fever) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lassa Fever (Lassa Hemorrhagic Fever) Companies Involved in Therapeutics Development

Celgene Corp

Etubics Corp

GeoVax Labs Inc

Inovio Pharmaceuticals Inc

Kineta Inc

Profectus BioSciences Inc

Lassa Fever (Lassa Hemorrhagic Fever) Drug Profiles

CC-11050 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GEOLM-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1400 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LHF-535 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ML-29 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Lassa Fever Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Lassa Fever Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-193 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lassa Fever (Lassa Hemorrhagic Fever) Dormant Projects

Lassa Fever (Lassa Hemorrhagic Fever) Product Development Milestones

Featured News & Press Releases

Oct 24, 2017: Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study

Jul 24, 2017: GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine

Jul 11, 2017: Tulane University awarded $12 million to create Lassa vaccine and treatment

Jul 10, 2017: GeoVax Reports Promising Results for Lassa Fever Vaccine

May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials

Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Lassa Fever (Lassa Hemorrhagic Fever) Pipeline by Celgene Corp, H1 2018

Lassa Fever (Lassa Hemorrhagic Fever) Pipeline by Etubics Corp, H1 2018

Lassa Fever (Lassa Hemorrhagic Fever) Pipeline by GeoVax Labs Inc, H1 2018

Lassa Fever (Lassa Hemorrhagic Fever) Pipeline by Inovio Pharmaceuticals Inc, H1 2018

Lassa Fever (Lassa Hemorrhagic Fever) Pipeline by Kineta Inc, H1 2018

Lassa Fever (Lassa Hemorrhagic Fever) Pipeline by Profectus BioSciences Inc, H1 2018

Lassa Fever (Lassa Hemorrhagic Fever) Dormant Projects, H1 2018

List of Figures

List of Figures

Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports